Titre:
  • High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
Auteur:Willemze, Roel; Suciu, Stefan; Meloni, Giovanna; Labar, Boris; Marie, Jean Pierre; Halkes, Constantijn CJ; Muus, Petra; Mistrik, Martin; Amadori, Sergio; Specchia, Giorgina; Fabbiano, Francesco; Nobile, Francesco; Sborgia, Marco; Camera, Andrea; Selleslag, Dominik; Lefrère, Francois; Magro, Domenico; Sica, Simona; Cantore, Nicola; Beksac, Meral Sinan; Berneman, Zwi; Thomas, Xavier; Melillo, Lorella; Guimaraes, Jose E; Leoni, Pietro; Luppi, Mario; Mitra, Maria E; Bron, Dominique; Fillet, Georges; Marijt, Erik EW; Venditti, Adriano; Hagemeijer, Anne; Mancini, M.; Jansen, Joop; Cilloni, Daniela; Meert, L; Fazi, Paola; Vignetti, Marco; Trisolini, Silvia SM; Mandelli, Franco; De Witte, Theo
Informations sur la publication:Journal of clinical oncology, 32, 3, page (219-228)
Statut de publication:Publié, 2014-01
Sujet CREF:Hématologie
MeSH keywords:Adolescent
Adult
Antimetabolites, Antineoplastic -- administration & dosage
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Consolidation Chemotherapy
Cytarabine -- administration & dosage
Daunorubicin -- administration & dosage
Drug Administration Schedule
Etoposide -- administration & dosage
Europe
Female
Humans
Induction Chemotherapy -- methods
Infusions, Intravenous
Leukemia, Myeloid, Acute -- diagnosis -- drug therapy -- genetics
Male
Middle Aged
Mutation
Risk Assessment
Risk Factors
Treatment Outcome
Langue:Anglais
Identificateurs:urn:issn:0732-183X
info:doi/10.1200/JCO.2013.51.8571
info:pii/JCO.2013.51.8571
info:pmid/24297940